

Claims

1. A compound which is hydrochloride salt of N-(2',4'-difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1'-biphenyl]-3-yl)cyclopropanesulfonamide (I) in crystalline form 8 characterized by a X-ray powder diffraction pattern comprising peaks at about 4.7, 14.2, 16.1, 18.0, 21.2, 23.5 and 26.5 degrees 2-theta.

~~2. A compound according to claim 1, which is in crystalline form.~~

~~3. A compound according to claim 2, which is in crystalline form 1 characterized by a X-ray powder diffraction pattern comprising peaks at about 4.6, 9.6, 18.7, 19.2, 23.5, 25.0 and 26.9 degrees 2-theta.~~

~~4. A compound according to claim 2, which is in crystalline form 3 characterized by a X-ray powder diffraction pattern comprising peaks at about 7.2, 9.2, 11.6, 16.1, 18.5, 25.9 and 27.9 degrees 2-theta.~~

~~5. A compound according to claim 2, which is in crystalline form 5 characterized by a X-ray powder diffraction pattern comprising peaks at about 8.3, 9.5, 18.5, 19.8, 21.1, 23.9, 25.1 and 27.4 degrees 2-theta.~~

~~6. A compound according to claim 2, which is in crystalline form 8 characterized by a X-ray powder diffraction pattern comprising peaks at about 4.7, 14.2, 16.1, 18.0, 21.2, 23.5 and 26.5 degrees 2-theta.~~

2. A compound according to claim 1, characterized by a X-ray powder diffraction pattern comprising peaks at about 4.7, 9.4, 14.2, 16.1, 16.9, 18.0, 18.5, 19.0, 21.2, 23.5, 24.0, 24.4, 25.3, 26.5, 27.5 and 29.5 degrees 2-theta.

~~73. A compound according to claim 61 or 2, which is a monohydrate.~~

~~8. A method of preparing a compound according to claim 3, comprising contacting compound (I) with a mixture of aqueous hydrochloric acid and acetone, and isolating the crystalline product.~~

~~9. A method of preparing a compound according to claim 4, comprising contacting compound (I) with a mixture of aqueous hydrochloric acid and ethanol, and isolating the crystalline product.~~

~~10. A method of preparing a compound according to claim 5, comprising grinding any crystalline form of hydrochloride salt of compound (I) in the presence of water, and isolating the crystalline product.~~

~~11. A method of preparing a compound according to any one of the preceding claims 6 or 7, comprising~~

- ~~(i) dissolving compound (I) in a mixture of water and 2-propanol in the presence of hydrochloric acid and formic acid at elevated temperature,~~
- ~~(ii) cooling the mixture, and~~
- ~~(iii) isolating the crystalline product.~~

~~12. A pharmaceutical dosage form comprising a compound according to any of claims 1 to 7.~~

~~13. A compound according to any of claims 1-7 to 3 for use in the treatment of cancer characterized by abnormal FGFR signalling.~~

~~14. A compound according to claim 13 wherein the cancer characterized by abnormal FGFR signalling is multiple myeloma, gastric cancer, endometrial cancer, prostate cancer, breast cancer, cholangiocarcinoma and uroepithelial carcinoma.~~